Regulatory MSD’s Keytruda-Padcev combo secures EC approval for MIBC Pharmaceutical Business ReviewThe authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy.OncologyRead full story pharminent June 25, 2026 (Last updated: June 25, 2026) Pharmaceutical Business Review The authorisation applies to adults with resectable MIBC who cannot be treated with cisplatin-based chemotherapy. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly launches its LillyDirect sales channel in the UKNext: FDA’s uniQure, REGENXBIO reversals could bolster other near-term rare disease applications Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
